However, since most COVID-19 vaccines on the market are based on the full-length membrane-bound S protein60, the results from our high-throughput fusion and expression assays, which are also based on full-length membrane-bound S protein, are directly applicable to COVID-19 vaccine development. This evidence concerns the gene PROS1 and COVID-19.